Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study.
Vivek NaranbhaiClaire A PernatAlexander GavralidisKerri J St DenisEvan C LamLaura M SpringSteven Jay IsakoffJocelyn R FarmerLeyre ZubiriGabriela S HobbsJoan HowAndrew M BrunnerAmir T FathiJennifer L PetersonMustafa SakhiGrace HambeltonElyssa N DenaultLindsey J MortensenLailoo A PerrielloMarissa N BrunoBrittany Y BertauxAleigha R LawlessMonica A JacksonElizabeth NiehoffCaroline BarabellChristian N NambuErika NakajimaTrenton ReinickeCynthia BowesCristhian J Berrios-MairenaOnosereme OfomanGrace E KirkpatrickJulia C ThieraufKerry Lynn ReynoldsHenning WillersWilfredo-Garcia BeltranAnand S DigheRebecca R SaffKimberly G BlumenthalRyan J SullivanYi-Bin ChenArthur Y KimAditya BardiaAlejandro B BalazsA John IafrateJustin F GainorPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Immune responses to SARS-CoV-2 vaccines are modestly impaired in patients with cancer. These data suggest utility of antibody testing to identify patients for whom additional vaccine doses may be effective and appropriate, although larger prospective studies are needed.